Background: At my shop we have changed wholesale to the use of tenecteplase over alteplase for acute ischemic stroke meeting criteria for thrombolytic therapy. This was based on a systematic review and meta-analysis of 6 RCTs and 2 observational trials …
In this 15-minute lecture from Rebellion in EM 2021, George Willis, MD discusses acute ischemic stroke and the evidence base for and against thrombolysis.
In this 9 minute video from day 2 of Rebellion in EM 2021, I go over the evidence for advanced imaging use in acute ischemic stroke of unknown time of onset to help guide treatment with intravenous alteplase.
Background: Alteplase has been the accepted thrombolytic for acute ischemic stroke (AIS) for 25 years. However, recent data has emerged regarding tenectaplase as an alternative. Tenecteplase is a modified form of alteplase, with a lower cost and more favorable pharmacokinetic …
Background: Intravenous alteplase is the current standard care for treatment of acute ischemic stroke (AIS) despite active debate on the research supporting its use. The window for its use has been restricted to <3h of symptom onset based on the …
© 2022 REBEL EM. All rights reserved. | Disclaimer | Website by Innov8 Place.
English
Chinese (Simplified)
French
German
Italian
Portuguese
Russian
Spanish
Turkish